查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2049362

蛋白質體學市場報告：按分析方法、成分類型、技術、應用、最終用戶和地區分類（2026-2034 年）

Proteomics Market Report by Analysis Type, Component Type, Technology, Application, End-User (Clinical Diagnostic Laboratories, Research Organizations, and Others), and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 139 Pages | 商品交期: 2-3個工作天內

價格

2025年全球蛋白質體學市場規模達472億美元。展望未來，IMARC Group預測，該市場將在2026年至2034年間以13.14%的複合年成長率成長，到2034年達到1,481億美元。目前，北美市場正處於領先地位，這得益於其強大的研究基礎設施以及眾多製藥和生物技術公司的積極佈局。該市場的主要驅動力來自質譜技術的快速發展、慢性病的盛行率上升以及個人化醫療的快速轉型。此外，機器學習（ML）和人工智慧（AI）的日益融合也提高了蛋白質分析和數據解讀的準確性。

市場規模及預測：

  • 預計到2025年，蛋白質體學市場價值將達到472億美元。
  • 預計從 2026 年到 2034 年，該市場將以 13.14% 的複合年成長率成長，到 2034 年達到 1,481 億美元。

主要部分：

  • 分析類型：根據分析類型，市場區隔分為結構蛋白質體學、功能性蛋白質體學和蛋白質表現蛋白質體學。
  • 組件類型：依組件類型，市場分為核心蛋白質體學服務及生物資訊軟體及相關服務。
  • 技術：蛋白質微陣列之所以成為市場領導者，是因為它們能夠快速且大規模分析蛋白質-蛋白質相互作用、表現和功能。其高通量特性使其成為生物標記發現和疾病診斷的理想選擇。
  • 應用領域：根據應用領域，市場可細分為蛋白質表現譜分析、蛋白質挖掘和轉譯後修飾。
  • 終端用戶：研究機構（藥物研發）佔據最大的市場佔有率，因為它們專注於識別生物標記和研究疾病機制。這些機構正在大力投資先進的蛋白質體學技術，以加速其研發活動。
  • 區域：北美憑藉其高額的研發投入以及眾多生物技術和製藥公司的存在，在蛋白質體學市場佔據領先地位。政府的支持、先進的醫療保健體係以及對創新技術的早期應用，進一步鞏固了該地區的市場主導地位。

主要公司：

  • 蛋白質體學市場的主要參與者包括安捷倫科技、Bio-Rad Laboratories、布魯克公司、 創新 Proteomics、丹納赫公司、GE醫療、堀場、Luminex公司、默克集團、珀金埃爾默、Promega公司、賽默飛世爾科技和沃特世公司。

市場成長的主要促進因素：

  • 對個人化醫療的需求日益成長：個人化醫療方法正在推動蛋白質體學工具在臨床和製藥領域的應用。蛋白質體學有助於識別特定的生物標記物，支持標靶藥物的研發，並有助於改善治療效果。
  • 癌症研究日益受到關注：蛋白質在腫瘤生物學、進展和抗藥性中發揮著至關重要的作用。蛋白質體學分析在識別癌症特異性生物標記、支持早期診斷和指南標靶治療發揮著至關重要的作用。這種研究需求正推動腫瘤學研究整體蛋白質體學技術的投資不斷增加。
  • 學術機構與生技公司之間的合作：夥伴關係正在加速蛋白質體學工具、診斷解決方案和治療方法的發展。這些共同努力能夠帶來更多資金籌措，拓展研究能力，並加強商業化進程。
  • 單細胞蛋白質體學的興起：單細胞蛋白質體學的發展使研究人員能夠在單一細胞層面上研究蛋白質表現。這項創新揭示了細胞多樣性和稀有細胞群，加速了對疾病的理解和藥物標靶化的研發。
  • 次世代定序（NGS）技術的進步：次世代定序的進步正在推動多體學研究方法的發展。 NGS數據為蛋白質表現研究提供了基因組背景，有助於生物標記的發現和精準醫療的改進。

未來展望：

  • 強勁成長前景：在個人化醫療需求旺盛以及質譜和生物資訊技術創新推動下，蛋白質體學市場預計將持續擴張。藥物發現和生物標記鑑定領域的持續研究也進一步促進了市場成長。
  • 市場演變：預計該領域將從基礎蛋白質分析轉向蛋白質微陣列和生物資訊學工具等先進技術。隨著生物學研究朝著更具針對性、數據驅動的方向發展，它將在診斷和個人化醫療中發揮關鍵作用。

由於單細胞蛋白質體學的興起，蛋白質體學市場正在不斷擴張。單細胞蛋白質體學能夠深入揭示細胞異質性，從而實現更精準的疾病建模和治療標靶識別。學術機構與生技公司之間的合作正在加速創新，並推動研究成果快速轉化為可操作的診斷和治療方案。質譜、蛋白質微陣列和次世代定序（NGS）等技術的進步也提高了數據準確性、處理能力和成本效益。蛋白質體學儀器的自動化和小型化提高了效率，減少了樣本用量，並降低了營運成本。此外，蛋白質體學與其他體學平台（如基因組學和代謝體學）的整合，實現了全面的生物學分析，並進一步擴展了其應用範圍。政府資助、對生物標記發現的監管支持以及蛋白質組學在農業和環境監測領域日益廣泛的應用，也促進了市場成長。

蛋白質體學市場的發展趨勢：

慢性疾病和感染疾病的發生率增加

慢性疾病和感染疾病的高發生率顯著推動了市場成長。隨著癌症、糖尿病、心血管疾病和感染疾病等疾病的日益普遍，人們越來越需要從分子層面了解疾病機制。根據美國國立衛生研究院 (NIH) 預測，到 2024 年，美國將新增 2,001,140 例癌症病例。蛋白質體學使研究人員和臨床醫生能夠識別疾病特異性生物標記、監測疾病進展並開發標靶治療。它在早期診斷中也發揮著至關重要的作用，而早期診斷對於有效管理慢性疾病至關重要。對個人化和精準醫療日益成長的需求進一步推動了蛋白質體學工具的應用，這些工具能夠對蛋白質-蛋白質相互作用和功能進行更深入的分析。

擴大製藥領域的研發活動

製藥業研發活動的擴張對市場產生了正面影響。根據《2025年瑞士生物技術報告》，瑞士2024年的研發支出達到26億瑞士法郎（約31.6億美元），其中14億瑞士法郎來自私人公司。隨著製藥公司專注於藥物發現和開發，對能夠深入了解蛋白質結構、功能和相互作用的先進工具的需求日益成長。蛋白質體學使研究人員能夠識別和檢驗潛在的藥物標靶，了解疾病通路，並在分子層面評估藥物的療效和毒性。隨著標靶治療的開發，蛋白質體學對於檢測疾病特異性生物標記和最佳化治療方法至關重要。此外，生物製藥和生物相似藥的日益普及也進一步增加了對精確蛋白質分析的需求。

擴大人工智慧的應用

人工智慧的日益普及正在推動更高效的數據分析、更精準的模式識別和更快速的生物標記發現。根據IMARC Group預測，2024年全球人工智慧市場規模將達1,156.2億美元。蛋白質體學產生龐大而複雜的資料集，需要藉助先進的計算工具才能進行準確解讀。人工智慧演算法，尤其是機器學習（ML），有助於識別與特定疾病相關的細微蛋白質表現模式，從而實現更快、更準確的診斷和藥物研發。人工智慧還能將蛋白質體學數據與其他生物資料集整合，進而增強個人化醫療中的預測建模能力。這種技術協同作用縮短了研究週期，並提高了學術研究和製藥研究的效率。此外，人工智慧驅動的自動化還能最大限度地減少人為錯誤，降低營運成本。隨著各機構將人工智慧融入其蛋白質體學工作流程，疾病檢測和治療領域的創新也不斷加速。蛋白質體學市場報告指出，這種技術趨勢正在塑造該產業的未來發展方向，並發揮著至關重要的作用。

蛋白質體學市場的主要成長要素：

學術機構與生技公司之間的合作關係

學術機構與生物技術公司之間日益密切的合作，透過將研究創新與商業性化應用相結合，顯著推動了蛋白質組學市場的成長。學術機構提供深厚的科學洞見和前沿發現，而生技公司則提供資源、基礎設施和專業知識，將這些洞見轉化為可市場化的應用。此類夥伴關係加速了新型蛋白質體學技術、診斷工具和治療方法的開發。合資企業有助於彌合基礎研究與臨床需求之間的差距，從而加快創新週期。這些合作通常能夠吸引來自公共和私營部門的資金籌措，從而進行大規模蛋白質體學研究並識別先進的生物標記。共享人才、設備和資料庫資源進一步提升了研究成果和商業性潛力。

單細胞蛋白質體學的興起

單細胞蛋白質體學的出現使研究人員能夠在單一細胞層級分析蛋白質，從而深入了解細胞異質性和疾病機制。與平均眾多細胞訊號的群體分析不同，單細胞技術能夠捕捉每個細胞獨特的蛋白質體學特徵，從而更深入地了解細胞行為、免疫反應和癌症進展。這種精細程度對於個人化醫療的發展至關重要，因為它有助於識別與疾病相關的罕見細胞類型和亞群。高解析度質譜和微流體平台的日益普及使得單細胞蛋白質體學更加可行和擴充性。隨著研究人員和製藥公司採用這種方法，生物標記發現和治療標靶識別的新途徑正在不斷湧現。

新一代定序技術（NGS）的技術進步

新一代定序（NGS）技術的進步正在增強多組體學整合，並拓展生物學見解的深度。儘管NGS主要用於基因組和轉錄組分析，但它與蛋白質體學的協同作用能夠更全面地理解細胞功能。研究人員可以將基因表現數據與蛋白質表現和修飾關聯起來，從而改善生物標記的識別和疾病建模。單細胞定序和空間轉錄組學等創新技術能夠高解析度地繪製組織內的基因和蛋白質網路圖譜。這些技術有助於基於基因組背景設計蛋白質體學實驗，從而提高實驗的準確性和相關性。此外，NGS的普及正在推動數據驅動的研究策略，並增加對互補蛋白質體學工具的需求。隨著NGS平台的不斷發展，它們在蛋白質體學市場的應用也持續成長和擴展。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球蛋白質體學市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依分析類型

  • 結構蛋白質體學
  • 功能蛋白質體學
  • 蛋白質表現蛋白質體學

第7章 市場區隔：依組件類型分類

  • 核心蛋白質體學服務
  • 生物資訊軟體及相關服務

第8章 市場區隔：依技術分類

  • 光譜學
  • 層析法
  • 電泳
  • 蛋白質微陣列
  • X光晶體學
  • 表面等離子體共振
  • 其他

第9章 市場區隔：依應用領域分類

  • 蛋白質表現譜分析
  • 蛋白質體挖掘
  • 轉譯後修飾

第10章 市場區隔：依最終用戶分類

  • 臨床檢查室
  • 研究機構（藥物研發）
  • 其他

第11章 市場區隔：按地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第12章 SWOT 分析

第13章：價值鏈分析

第14章：波特五力分析

第15章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Agilent Technologies Inc.
    • Bio-RAD Laboratories Inc.
    • Bruker Corporation
    • Creative Proteomics
    • Danaher Corporation
    • GE Healthcare Inc.
    • Horiba Ltd.
    • Luminex Corporation
    • Merck Group
    • Perkinelmer Inc.
    • Promega Corporation
    • Thermo Fisher Scientific Inc.
    • Waters Corporation
Product Code: SR112026A2156

The global proteomics market size reached USD 47.2 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 148.1 Billion by 2034, exhibiting a growth rate (CAGR) of 13.14% during 2026-2034. North America currently dominates the market, driven by its robust research infrastructure and strong presence of pharmaceutical and biotech companies. The market is primarily driven by rapid technological advancements in mass spectrometry, increasing incidents of chronic diseases, and rapid shift towards personalized medicines. Moreover, increasing integration of machine learning (ML) and artificial intelligence (AI) are upgrading protein analysis and data interpretation.

MARKET SIZE & FORECASTS:

  • Proteomics market was valued at USD 47.2 Billion in 2025.
  • The market is projected to reach USD 148.1 Billion by 2034, at a CAGR of 13.14% from 2026-2034.

DOMINANT SEGMENTS:

  • Analysis Type: On the basis of analysis type, the market has been segmented into structural proteomics, functional proteomics, and protein expression proteomics.
  • Component Type: Based on component type, the market has been bifurcated into core proteomics services and bioinformatics software and related services.
  • Technology: Protein microarrays lead the market as they enable rapid, large-scale analysis of protein interactions, expressions, and functions. Their high-throughput nature makes them ideal for biomarker discovery and disease diagnostics.
  • Application: On the basis of application, the market has been classified into protein expression profiling, protein mining, and post-translational modifications.
  • End-User: Research organizations (drug discovery) hold the biggest market share because of their focus on biomarker identification and disease mechanism studies. They are heavily investing in advanced proteomic technologies to accelerate research and development (R&D) activities.
  • Region: North America leads the proteomics market due to high R&D investments and a large presence of biotech and pharmaceutical companies. Government support, advanced healthcare systems, and early adoption of innovative technologies are further driving market leadership in the region.

KEY PLAYERS:

  • The leading companies in proteomics market include Agilent Technologies Inc., Bio-RAD Laboratories Inc., Bruker Corporation, Creative Proteomics, Danaher Corporation, GE Healthcare Inc., Horiba Ltd., Luminex Corporation, Merck Group, Perkinelmer Inc., Promega Corporation, Thermo Fisher Scientific Inc., Waters Corporation, etc.

KEY DRIVERS OF MARKET GROWTH:

  • Growing Demand for Personalized Medicine: The personalized approach fosters greater adoption of proteomic tools in clinical and pharmaceutical settings. Proteomics identifies specific biomarkers, supporting targeted drug development and improving therapeutic outcomes.
  • Rising Focus on Cancer Research: Proteins play a crucial role in tumor biology, progression, and drug resistance. Proteomic analysis helps identify cancer-specific biomarkers, supports early diagnosis, and guides targeted therapy. This research demand is enhancing investments in proteomic technologies across oncology studies.
  • Collaborations Between Academic Institutes and Biotech Companies: Partnerships are facilitating faster development of proteomic tools, diagnostic solutions, and therapeutics. Joint efforts also attract more funding, expand research capacity, and strengthen commercialization pipelines.
  • Emergence of Single-Cell Proteomics: The development of single-cell proteomics is allowing researchers to study protein expression at the individual cell level. This innovation reveals cellular diversity and rare populations, enhancing disease understanding and drug targeting.
  • Technological Advancements in Next-Generation Sequencing (NGS): Advancements in next-generation sequencing are enabling multi-omics approaches. NGS data provides genomic context for protein expression studies, improving biomarker discovery and precision medicine.

FUTURE OUTLOOK:

  • Strong Growth Outlook: The proteomics market is expected to see sustained expansion, due to high demand for personalized medicine and innovations in mass spectrometry and bioinformatics. Ongoing research in drug discovery and biomarker identification is further supporting the market expansion.
  • Market Evolution: The sector is anticipated to shift from basic protein analysis to advanced techniques like protein microarrays and bioinformatics tools. It is playing a significant role in diagnostics and personalized medicine, reflecting a shift towards more targeted and data-based biological investigations.

The proteomics market is expanding due to the rise of single-cell proteomics, which offers deep insights into cellular heterogeneity, enabling more accurate disease modeling and therapeutic targeting. Collaborations between academic institutions and biotech companies are accelerating innovations, allowing quicker translation of research into practical diagnostic and therapeutic solutions. Technological advancements in mass spectrometry, protein microarrays, and NGS are also enhancing data accuracy, throughput, and cost-efficiency. Improved automation and miniaturization of proteomics instruments are refining efficiency, reducing sample volumes, and lowering operational costs. Moreover, the integration of proteomics with other omics platforms like genomics and metabolomics is enabling comprehensive biological analysis, further broadening its applications. Government funding, regulatory support for biomarker discovery, and increasing utilization of proteomics in agriculture and environmental monitoring are also contributing to the market growth.

PROTEOMICS MARKET TRENDS:

Growing incidence of chronic and infectious diseases

High incidence of chronic and infectious ailments is significantly fueling the growth of the market. As conditions like cancer, diabetes, cardiovascular disorders, and infectious diseases are becoming more widespread, there is a rising need to understand disease mechanisms at the molecular level. As per the NIH, in 2024, it was anticipated that there would be 2,001,140 new cancer cases in the United States. Proteomics enables researchers and clinicians to identify disease-specific biomarkers, monitor disease progression, and develop targeted therapies. It also aids in early diagnosis, which is critical in managing chronic illnesses effectively. The demand for personalized medicine and precision treatment is further promoting the use of proteomics tools, as they allow a deeper analysis of protein interactions and functions.

Increasing pharmaceutical R&D activities

The growing pharmaceutical R&D activities are positively influencing the market. As stated in the Swiss Biotech Report 2025, R&D expenditure in Switzerland amounted to SFr2.6 Billion (USD 3.16 Billion) in 2024, with SFr1.4 Billion contributed by private companies. As pharmaceutical companies are wagering on drug discovery and development, there is a rising demand for advanced tools that can offer insights into protein structures, functions, and interactions. Proteomics enables researchers to identify and validate potential drug targets, understand disease pathways, and assess drug efficacy and toxicity at the molecular level. With a strong focus on developing targeted therapies, proteomics is becoming essential for detecting disease-specific biomarkers and tailoring treatments accordingly. Additionally, the adoption of biologics and biosimilars has further intensified the need for precise protein analysis.

Rising AI adoption

Increasing AI adoption is streamlining data analysis, improving pattern recognition, and accelerating biomarker discovery. As per the IMARC Group, the global AI market size was valued at USD 115.62 Billion in 2024. Proteomics generates massive, complex datasets that require advanced computational tools for accurate interpretation. AI algorithms, particularly ML, help identify subtle protein expression patterns linked to specific diseases, enabling faster and more precise diagnostics and drug development. AI also enhances predictive modeling in personalized medicine by integrating proteomic data with other biological datasets. This technological synergy reduces research timelines and boosts efficiency in both academic and pharmaceutical research. Furthermore, AI-oriented automation minimizes human error and lowers operational costs. As organizations are integrating AI into their proteomics workflows, innovations in disease detection and treatment continue to advance rapidly. According to the proteomics market report, this technological trend plays an important role in shaping the future of the industry.

KEY GROWTH DRIVERS OF PROTEOMICS MARKET:

Partnerships between academic institutes and biotech companies

Increasing alliances between academic institutes and biotech companies are significantly bolstering the proteomics market growth by combining research innovations with commercial execution. Academic institutions offer deep scientific knowledge and cutting-edge discoveries, while biotech firms provide resources, infrastructure, and expertise to translate these findings into market-ready applications. Such partnerships accelerate the development of novel proteomic technologies, diagnostic tools, and therapeutics. Joint ventures help bridge the gap between basic research and real-world clinical needs, leading to faster innovation cycles. These collaborations often attract funding from both public and private sectors, enabling large-scale proteomic studies and advanced biomarker identification. The shared access to talent, equipment, and databases is further strengthening research output and commercial potential.

Emergence of single-cell proteomics

The emergence of single-cell proteomics is allowing researchers to analyze proteins at an individual cell level, offering insights into cellular heterogeneity and disease mechanisms. Unlike bulk analysis, which averages signals from numerous cells, single-cell techniques capture the unique proteomic profile of each cell, enabling deeper understanding of cell behavior, immune responses, and cancer progression. This level of granularity is crucial for developing personalized medicine, as it helps identify rare cell types or subpopulations involved in disease. The growing utilization of high-resolution mass spectrometry and microfluidic platforms has made single-cell proteomics more feasible and scalable. As researchers and pharmaceutical companies are adopting this approach, it is opening new avenues for biomarker discovery and therapeutic targeting.

Technological advancements in NGS

Technological advancements in NGS are enhancing multi-omics integration and expanding the depth of biological insights. While NGS is primarily used for genomic and transcriptomic analysis, its synergy with proteomics allows a more complete understanding of cellular function. Researchers can correlate gene expression data with protein expression and modifications, leading to improved biomarker identification and disease modeling. Innovations, such as single-cell sequencing and spatial transcriptomics, are enabling high-resolution mapping of gene and protein networks within tissues. These technologies make it easier to design proteomic experiments informed by genomic context, enhancing accuracy and relevance. The widespread availability of NGS also fosters data-driven research strategies, driving the demand for complementary proteomics tools. As NGS platforms are evolving, they continue to support and broaden applications in the proteomics market.

PROTEOMICS MARKET SEGMENTATION:

Breakup by Analysis Type:

  • Structural Proteomics
  • Functional Proteomics
  • Protein Expression Proteomics

Structural proteomics is concerned with detailed analysis of protein interactions, structures, and functions. This field is required for studying disease mechanism and drug development. Advanced instruments and techniques boost growth, facilitating high-resolution structural comprehensions. Leading research institutions and companies are globally investing in structural proteomics to develop innovative therapeutic solutions.

Functional proteomics emphasizes on recognizing protein interactions and functions within a biological context. This discipline leverages advanced techniques to examine the dynamics of protein modifications, activities, and networks. In the global proteomics market, functional proteomics plays a crucial role by spurring innovations in personalized medicine, drug discovery, and disease diagnostics. By offering discernments into protein pathways and mechanisms, it encourages the development of targeted therapies and biomarker identification, substantially improving the efficacy and accuracy of medical treatments.

Protein expression proteomics examines the qualitative and quantitative aspects of protein formation within cells. It includes high-throughput techniques to compare and profile protein expression levels across various treatments or conditions. In the global proteomics market outlook, this subfield is pivotal for comprehending disease mechanisms, identifying biomarkers, and innovating novel therapeutic strategies. The proficiency of monitoring protein expression changes in response to numerous stimuli facilitates the development of enhanced and effective personalized medical initiatives and early detection of diseases.

Breakup by Component Type:

  • Core Proteomics Services
  • Bioinformatics Software and Related Services

Core proteomics services include the protein identification, quantification, and analysis by leveraging advanced techniques such as chromatography and mass spectrometry. These services permit researchers to interpret complex protein interactions and functions, streamlining discoveries in therapeutic targets, disease mechanisms, and biomarker identification. Specialization in data acquisition, interpretation, and sample preparation is crucial for accurate results.

Bioinformatics software and related services provide crucial tools for data visualization and analysis. These services feature algorithms for protein structural prediction, sequence alignment, and functional annotation. Incorporating bioinformatics with proteomics propels research by reconfiguring raw data into meaningful biological insights, endorsing advancements in drug development and personalized medicine. For instance, in October 2023, Ionpath, a high-definition spatial proteomics developer, launched user-friendly bioinformatics tools named MIBIplus and MIBIsight that offers controlled data interpretation by using mass spectrometry to study various proteins associated with immune-oncology.

Breakup by Technology:

  • Spectroscopy
  • Chromatography
  • Electrophoresis
  • Protein Microarrays
  • X-Ray Crystallography
  • Surface Plasmon Resonance
  • Others

Protein microarrays represent the leading market segment

Protein microarrays demonstrate a high-throughput platform in proteomics market, allowing simultaneous analysis of numerous protein samples. By immobilizing proteins on solid surfaces, these arrays foster rapid quantification and detection, promoting therapeutic development, biomarker discovery and diagnostics within the global proteomics market. For instance, in February 2024, Infinity Bio launched new technology, based on MIPSA technology, that leverages protein microarray method to analyze antibody-antigen binding. Maryland-based PTX Capital and Blackbird BioVentures granted USD 4 million fund to Infinity for the development of this technology, allowing the production of large arrays of proteins or peptides in a highly programmed manner. It also aids in combining full-length proteins and peptides in a single reaction, which allows researchers to study antibodies interaction with the 3D structure of full proteins and collect information on the specific peptide sequences that function as antibody epitopes.

Breakup by Application:

  • Protein Expression Profiling
  • Proteome Mining
  • Post-translational Modifications

Protein expression profiling is a pivotal technique permitting the quantification and identification of proteins within a specific biological sample. This process offers valuable analysis of disease mechanisms and cellular functions, promoting the development of personalized medicine and targeted therapeutics by locating specific protein markers associated with numerous conditions.

Proteome mining is an inclusive approach that encompasses the systematic assessment of the entire proteome to discover novel proteins and apprehend their functions. This method propels advancements in drug development and biomarker discovery, presenting an in-depth understanding of potential therapeutic targets and biological processes for numerous diseases.

Post-translational modification (PTM) analysis targets the chemical modifications post the synthesis of proteins. These modifications greatly influence protein stability, function, and interactions. In the global proteomics market, PTM analysis aids in elucidating complex regulatory mechanisms, promoting the development of innovative diagnostics and treatments.

Breakup by End-User:

  • Clinical Diagnostic Laboratories
  • Research Organizations (Drug Discovery)
  • Others

Research organizations dominate the market

By utilizing proteomic data, research organizations uncover new drug targets, expound disease mechanisms, and boost the development of effective treatments, consequently spurring advancements in biotechnological and pharmaceutical sectors. For instance, in July 2024, Olink Holding AB, a leading proteomics company, launched its network of Olink Certified Service Providers that will represent service labs and contract research organization (CROs) worldwide.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest proteomics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market, holding the largest share of the proteomics market revenue.

The market in North America is undergoing notable growth, principally driven by significant investments in research and development, and upgraded healthcare infrastructure. Furthermore, the increasing incidents of chronic diseases and intensifying focus on personalized medicine is boosting the market growth. In additional, robust support by government and funding initiatives escalate the utilization of proteomics technology in academic and clinical research. For instance, in September 2023, Multiomics CRO Psomagen launched its Spatial Biology services for 10X Genomics Xenium in North America. Psomagen's Xenium Service integrates various omics platforms, including proteomics, genomics, and transcriptomics.

COMPETITIVE LANDSCAPE:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the proteomics industry include Agilent Technologies Inc., Bio-RAD Laboratories Inc., Bruker Corporation, Creative Proteomics, Danaher Corporation, GE Healthcare Inc., Horiba Ltd., Luminex Corporation, Merck Group, Perkinelmer Inc., Promega Corporation, Thermo Fisher Scientific Inc., Waters Corporation, etc.
  • The competitive landscape of the global proteomics market is represented by the presence of major companies that are actively competing to strengthen their market position through strategic collaborations and technological advancements. For instance, in April 2024, Biognosys and Alamar Biosciences announced that they have entered into a strategic partnership for joint scientific research in biofluid-based proteomics. This partnership brings together Biognosys' expertise in data independent acquisition mass spectrometry (DIA-MS) and Alamar's cutting-edge immunoassays. Market players are currently emphasizing on research and development investment and expansion of their product portfolios to lead this swiftly evolving sector. Acquisitions and mergers are also common, aimed at unifying resources and expertise. The market is currently experiencing intense competition, fueled by escalating demand for advanced diagnostic tools and precision medicine, mandating continuous innovation.

Key Questions Answered in This Report

1. How big is the global proteomics market?

2. What is the expected growth rate of the global proteomics market during 2026-2034?

3. What are the key factors driving the global proteomics market?

4. What has been the impact of COVID-19 on the global proteomics market?

5. What is the breakup of the global proteomics market based on the technology?

6. What is the breakup of the global proteomics market based on the end-user?

7. What are the key regions in the global proteomics market?

8. Who are the key players/companies in the global proteomics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Proteomics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Analysis Type

  • 6.1 Structural Proteomics
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Functional Proteomics
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Protein Expression Proteomics
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Component Type

  • 7.1 Core Proteomics Services
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Bioinformatics Software and Related Services
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Technology

  • 8.1 Spectroscopy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Chromatography
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Electrophoresis
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Protein Microarrays
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 X-Ray Crystallography
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Surface Plasmon Resonance
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast
  • 8.7 Others
    • 8.7.1 Market Trends
    • 8.7.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Protein Expression Profiling
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Proteome Mining
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Post-translational Modifications
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by End-User

  • 10.1 Clinical Diagnostic Laboratories
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Research Organizations (Drug Discovery)
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Others
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Agilent Technologies Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Bio-RAD Laboratories Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Bruker Corporation
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Creative Proteomics
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
    • 15.3.5 Danaher Corporation
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 GE Healthcare Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Horiba Ltd.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
    • 15.3.8 Luminex Corporation
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Merck Group
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Perkinelmer Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Promega Corporation
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
    • 15.3.12 Thermo Fisher Scientific Inc.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Waters Corporation
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Proteomics Market: Major Drivers and Challenges
  • Figure 2: Global: Proteomics Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Proteomics Market: Breakup by Analysis Type (in %), 2025
  • Figure 4: Global: Proteomics Market: Breakup by Component Type (in %), 2025
  • Figure 5: Global: Proteomics Market: Breakup by Technology (in %), 2025
  • Figure 6: Global: Proteomics Market: Breakup by Application (in %), 2025
  • Figure 7: Global: Proteomics Market: Breakup by End-User (in %), 2025
  • Figure 8: Global: Proteomics Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Proteomics Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 10: Global: Proteomics (Structural Proteomics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Proteomics (Structural Proteomics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Proteomics (Functional Proteomics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Proteomics (Functional Proteomics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Proteomics (Protein Expression Proteomics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Proteomics (Protein Expression Proteomics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Proteomics (Core Proteomics Services) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Proteomics (Core Proteomics Services) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Proteomics (Bioinformatics Software and Related Services) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Proteomics (Bioinformatics Software and Related Services) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Proteomics (Spectroscopy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Proteomics (Spectroscopy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Proteomics (Chromatography) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Proteomics (Chromatography) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Proteomics (Electrophoresis) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Proteomics (Electrophoresis) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Proteomics (Protein Microarrays) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Proteomics (Protein Microarrays) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Proteomics (X-Ray Crystallography) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Proteomics (X-Ray Crystallography) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Proteomics (Surface Plasmon Resonance) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Proteomics (Surface Plasmon Resonance) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Proteomics (Others) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Proteomics (Others) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Proteomics (Protein Expression Profiling) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Proteomics (Protein Expression Profiling) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Global: Proteomics (Proteome Mining) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Global: Proteomics (Proteome Mining) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Global: Proteomics (Post-translational Modifications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Global: Proteomics (Post-translational Modifications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Global: Proteomics (Clinical Diagnostic Laboratories) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Global: Proteomics (Clinical Diagnostic Laboratories) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Global: Proteomics (Research Organizations-Drug Discovery) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Global: Proteomics (Research Organizations-Drug Discovery) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Global: Proteomics (Other End-Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Global: Proteomics (Other End-Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: North America: Proteomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: North America: Proteomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: United States: Proteomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: United States: Proteomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Canada: Proteomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Canada: Proteomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Asia Pacific: Proteomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Asia Pacific: Proteomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: China: Proteomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: China: Proteomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Japan: Proteomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Japan: Proteomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: India: Proteomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: India: Proteomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: South Korea: Proteomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: South Korea: Proteomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Australia: Proteomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Australia: Proteomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Indonesia: Proteomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Indonesia: Proteomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Others: Proteomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Others: Proteomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Europe: Proteomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Europe: Proteomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Germany: Proteomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Germany: Proteomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: France: Proteomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: France: Proteomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: United Kingdom: Proteomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: United Kingdom: Proteomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Italy: Proteomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Italy: Proteomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Spain: Proteomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Spain: Proteomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Russia: Proteomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Russia: Proteomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Others: Proteomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: Others: Proteomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Latin America: Proteomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 85: Latin America: Proteomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: Brazil: Proteomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 87: Brazil: Proteomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 88: Mexico: Proteomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 89: Mexico: Proteomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 90: Others: Proteomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 91: Others: Proteomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 92: Middle East and Africa: Proteomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 93: Middle East and Africa: Proteomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 94: Global: Proteomics Industry: SWOT Analysis
  • Figure 95: Global: Proteomics Industry: Value Chain Analysis
  • Figure 96: Global: Proteomics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Proteomics Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Proteomics Market Forecast: Breakup by Analysis Type (in Million USD), 2026-2034
  • Table 3: Global: Proteomics Market Forecast: Breakup by Component Type (in Million USD), 2026-2034
  • Table 4: Global: Proteomics Market Forecast: Breakup by Technology (in Million USD), 2026-2034
  • Table 5: Global: Proteomics Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 6: Global: Proteomics Market Forecast: Breakup by End-User (in Million USD), 2026-2034
  • Table 7: Global: Proteomics Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 8: Global: Proteomics Market Structure
  • Table 9: Global: Proteomics Market: Key Players